Zobrazeno 1 - 10
of 786
pro vyhledávání: '"Stefan Faderl"'
Autor:
Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prebet
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly diagnosed, high-risk/secondar
Externí odkaz:
https://doaj.org/article/7ce79d8eaa0b49f4be67f0982b9fa4f2
P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
Autor:
Joshua D. Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Nalina Dronamraju, Stefan Faderl, Tara L. Lin, Geoffrey L. Uy, Jeffrey Lancet, Jorge Cortes
Publikováno v:
HemaSphere, Vol 7, p e178806c (2023)
Externí odkaz:
https://doaj.org/article/ec6130b6a6d24b849b28a4a9c906898e
Autor:
Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-9 (2021)
Abstract Background CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults
Externí odkaz:
https://doaj.org/article/6d4b5e14c72d4124802916e5e4a4cda2
Autor:
Marina Konopleva, Peter F. Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, Sergej Konoplev, Yongchuan Gu, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah Thomas, Jorge Cortes, Tapan Kadia, Steven Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, Jennie Feliu, Hongbo Lu, Caimiao Wei, William R. Wilson, Teresa J. Melink, John C. Gutheil, Michael Andreeff, Elihu H. Estey, Hagop Kantarjian
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-1
Externí odkaz:
https://doaj.org/article/9b9128ff96344fda8aed35d1dfe2946a
Autor:
Paolo Strati, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan Burger, Stefan Faderl, Francesco Paolo Tambaro, Nitin Jain, William G. Wierda
Publikováno v:
Haematologica, Vol 99, Iss 8 (2014)
Although uncommon in treatment-naive patients with chronic lymphocytic leukemia, deletion 17p is a high-risk disease characteristic. We analyzed and reported outcomes for 63 patients with deletion 17p chronic lymphocytic leukemia who received first-l
Externí odkaz:
https://doaj.org/article/69075230eca64b7290b8ae31aa0adf87
Autor:
Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J. Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes
Publikováno v:
Haematologica, Vol 98, Iss 2 (2013)
We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias. Twenty-eight patients received the construct intra
Externí odkaz:
https://doaj.org/article/9fbeb5ba6ab54ef3bacf594a76ad99bf
Autor:
Aziz Nazha, Jorge Cortes, Stefan Faderl, Sherry Pierce, Naval Daver, Tapan Kadia, Gautam Borthakur, Raja Luthra, Hagop Kantarjian, Farhad Ravandi
Publikováno v:
Haematologica, Vol 97, Iss 8 (2012)
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations are among the most frequent molecular aberrations in patients with acute myeloid leukemia. We retrospectively analyzed 324 patients with acute myeloid leukemia treated with f
Externí odkaz:
https://doaj.org/article/cd46a93c3dc040e8baa591817e3825c3
Autor:
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation. It is unclear in
Externí odkaz:
https://doaj.org/article/4cb81d6d3647428bb7a565e7244db138
Autor:
Gautam Borthakur, Hagop Kantarjian, Farhad Ravandi, Weiguo Zhang, Marina Konopleva, John J. Wright, Stefan Faderl, Srdan Verstovsek, Sheela Mathews, Michael Andreeff, Jorge E. Cortes
Publikováno v:
Haematologica, Vol 96, Iss 1 (2011)
Background Sorafenib is a multi-kinase inhibitor with activity against fms-like tyrosine kinase 3 with internal tandem duplication mutation and Raf kinase among others. A phase I dose escalation study of sorafenib was conducted in patients with advan
Externí odkaz:
https://doaj.org/article/ddefba7d16644d1e9feb6b5a89b0d9ae
Autor:
Jayastu Senapati, Emmanuel Huante Almanza, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Publikováno v:
Blood. 140:9050-9053
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2e0a0d66dbdab667374ac4088899bd2
https://doi.org/10.1182/blood-2022-171011
https://doi.org/10.1182/blood-2022-171011